Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership

Mar 18 2024

• By Michael McCaughan

Elderly-woman-doing-brain-jigsaw — • Source: Shutterstock

Related Content

US FDA Neuroscience Office Director Billy Dunn Departs As Agency Faces New Review Challenges

Feb 27 2023

A New Direction for Alzheimer’s R&D: FDA Outlines Early Disease Pathway

Apr 29 2013

Alzheimer’s And Surrogate Endpoints: FDA’s On A Case-By-Case Basis Per New Guidance

Mar 11 2024

Early Alzheimer’s Guidance: FDA Puts Forth New Endpoint Possibilities for Stage 3 Disease

Mar 12 2024

Related Companies

Biogen, Inc.

Eisai Co., Ltd.

Additional Topics

United States Guidance Documents Drug Approval Standards Leadership FDA Regulation Neurology BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window